SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients

Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which produces high remission rates among older patients with AML at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

Share this video  
Similar topics